NCT07579949
A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved at least 6 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Mar 29, 2027 to Sep 30, 2027 Show 5 more changesShow less
- Recruitment opened
- Eligibility criteria expanded, about 31 words
- Study completion pushed from Apr 29, 2027 to Dec 30, 2027
- Start date changed from estimate of Jun 18, 2026 to Jun 16, 2026
- Site details revised at 8 of 8 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety evaluation
Timeframe: From signing the informed consent to 4 weeks after the last dose
Arms and interventions
Cohort 1Experimental
Study Drug
Cohort 2Experimental
Study Drug
Cohort 3Placebo comparator
Placebo
Drugs: SNH-119014 dose 1, SNH-119014 dose 2, Placebo
Sites
8 sites in 1 country